로딩 중…
지수 로딩 중…
파로스아이바이오
388870· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩6,260-4.43%
2026-06-19
Price Chart
파로스아이바이오+1.46%
Financials
No data
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 81.04B KRW |
| Net Income | -9.94B KRW |
| Total Assets | 27.96B KRW |
| Net Assets | 11.87B KRW |
| Employees | 32 |
| Value | |
| P/B | 6.83x |
| FCF Yield | -10.32% |
| Profitability | |
| ROE | -83.71% |
| ROA | -35.53% |
| Financial Health | |
| Debt Ratio | 235.61% |
| Total Debt | 8.15B KRW |
| FCF | -8.36B KRW |
| Cash | 7.27B KRW |
| Current Ratio | 23.69x |
| Performance | |
| 1Y Return | 1.46% |
| 1M Return | -7.67% |
| From 52W High | -48.35% |
| 1Y MDD | -48.28% |
| Trading | |
| Volume | 83,337 shares |
| Foreign Own. | 2.61% |
| Per Share | |
| EPS | -768 KRW |
| BPS | 917 KRW |
Company Info
Pharos iBio, established in 2016 and listed on KOSDAQ in 2023 as a technology growth company, specializes in new drug development. The company operates an AI-based new drug development platform, Chemibus, integrating large-scale compound big data and multi-omics analysis technology. It focuses on innovative new drug development for rare and intractable diseases, particularly in oncology. Its flagship pipeline, PHI-101, has received orphan drug designation, aiming to accelerate development and enhance market competitiveness. Pharos iBio is headquartered in Anseong-si, Gyeonggi-do.